<p>China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources BOYA Biotechnology Group received the Clinical Trial Approval Notice for Human Coagulation Factor IX issued by the National Medical Products Administration. This product is used for bleeding treatment in patients with Coagulation Factor IX deficiency (Hemophilia B)</p>

588130

159892

159316

<p>China Resources Pharma announced that its subsidiary China Resources BOYA Biotechnology Group has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for human coagulation factor IX. This product is used for bleeding treatment in patients with coagulation factor IX deficiency (Hemophilia B)</p>

AASTOCKS

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

BOYA BIOLOGY

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CHINARES PHARMA

Penghua CSI HK Connect Health Care Composite ETF

China Universal 800 Health Care ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China